PORTAL: Program on Regulation, Therapeutics, and Law
  • About Us
    • What is PORTAL?
    • Core Faculty
    • Research Team
    • Affiliated Faculty & Researchers
    • Expert Roundtable
  • Our Work
    • Publications
    • Policy Action
    • Literature Scan
    • In the Press
    • Media Center
    • Teaching
    • CeBIL
    • Biomarkers >
      • About The Project
      • The PBRC Team
      • Our Collaborators
      • AERO Graph
      • Workshops
      • Biomarkers2018
    • FDA REMS
  • Blog
  • Events
    • #policyethx 2020-2021
    • Events Archive >
      • #policyethx 2019-2020
      • #policyethx 2018-2019
      • #policyethx 2017-2018
      • #policyethx 2016-2017
      • Biosimilar Insulin
      • Older Events
  • Join Us
    • PORTAL Fellowships
    • Program Coordinator
  • Contact
    • Inquiries
    • E-mail List
  • About Us
    • What is PORTAL?
    • Core Faculty
    • Research Team
    • Affiliated Faculty & Researchers
    • Expert Roundtable
  • Our Work
    • Publications
    • Policy Action
    • Literature Scan
    • In the Press
    • Media Center
    • Teaching
    • CeBIL
    • Biomarkers >
      • About The Project
      • The PBRC Team
      • Our Collaborators
      • AERO Graph
      • Workshops
      • Biomarkers2018
    • FDA REMS
  • Blog
  • Events
    • #policyethx 2020-2021
    • Events Archive >
      • #policyethx 2019-2020
      • #policyethx 2018-2019
      • #policyethx 2017-2018
      • #policyethx 2016-2017
      • Biosimilar Insulin
      • Older Events
  • Join Us
    • PORTAL Fellowships
    • Program Coordinator
  • Contact
    • Inquiries
    • E-mail List
Picture
PORTAL runs a monthly seminar series that convenes two experts from different fields or vantage points to discuss how various aspects of therapeutic development and use are affected by ethical norms, laws, and regulations. These are organized in conjunction with the HMS Center for Bioethics  supported by the Oswald DeN. Cammann Fund at Harvard University.

You may join the discussion on Twitter before, during, or after each event by following 
@PORTAL_Research and using the hashtag #policyethx.

Health Policy & Bioethics Consortia 2016-2017

Private Investment vs. Public Funding in Therapeutic Development
​

May 12, 2017 | Harvard Medical School

There is substantial controversy around the contributions of different sectors in the biomedical research community towards the creation of highly innovative products. Emerging research has also pointed to the valuable, yet under-recognized, role played by public investment. By contrast, the pharmaceutical industry has long contended that it is responsible for most new medicines. In recent years, some large academic centers have actively sought out private funding, including venture capitalists, in supporting their research. What are the implications of different economic models of funding biomedical sciences for the types of products that emerge, and for the ultimate goal of improving patient care options?
Picture
EXPERTS:
Terry McGuire, MS, MBA
​Founding Partner, Polaris Partners

​
Bhaven Sampat, PhD
Professor of Health Policy and Management
​Columbia University Mailman School of Public Health

MODERATOR:
​Ariel D. Stern, MA, PhD

Assistant Professor of Business Administration
Technology and Operations Management Unit
Harvard Business School


Medical Errors and the Culture of Medicine
​

April 14, 2017 | Harvard Medical School

​With decades of experience behind the patient safety movement, we now have a clear understanding of the importance of preventing medical errors. However, progress in this area has been mixed, with the field still struggling with fundamental questions: how reliably can we identify errors and determine whether a death was preventable? Does this heightened focus on patient safety further the perception that death is most often the result of mistakes that can be avoided? And how can we most effectively scrutinize our practices and improve outcomes?
EXPERTS:
Timothy Hofer, MD
Professor of Internal Medicine
Associate Director for Analytic and
​Information Resources
​University of Michigan
​
Martin Makary, MD, MPH
Professor of Surgery
​Johns Hopkins University School of Medicine
Professor of Health Policy & Management
Johns Hopkins Bloomberg School of Public Health

MODERATOR:
​
Chana Sacks, MD
HMS General Internal Medicine fellow
Picture

Promoting Accurate and Useful Public Reporting on Physicians

March 29, 2017 | Harvard Medical School

​Public reporting has been proposed as a tool for improving the transparency and quality of health care delivery. Hospitals now dedicate substantial resources towards reporting requirements for measures such as mortality for selected conditions (e.g. pneumonia, heart failure) and outcomes of cardiac procedures. However, the enormous effort and expense supporting public reporting have raised questions about whether such programs actually improve public health, or may even be misleading or harmful. For example, risk adjustment tools may lack the refinement necessary to yield sound results, forcing a delicate balance between providing more information to the public with only limited context. Also, there may be potential unintended consequences of public reporting, such as adverse selection, that may actually worsen clinical outcomes. What, ultimately, are the ways in which public reporting can be shaped to improve quality of care, transparency, and outcomes?
Picture
EXPERTS:
Robert Yeh, MD, MBA

Director, Richard and Susan Smith Center for Outcomes Research in Cardiology
​Beth Israel Deaconess Medical Center and Harvard Medical School

​
Thomas Lee, MD
Chief Medical Officer
​Press Ganey

MODERATOR:
​
Daniel B. Kramer, MD
Assistant Professor of Medicine, HMS & 
Cardiac Electrophysiologist, Div. of Cardiovascular Medicine & the Cardiovascular Institute, ​​Beth Israel Deaconess Medical Center

Returning Results to Research Participants
February 10, 2017 | Harvard Law School

​
Clinical investigators, public health advocates, and institutional review boards have been struggling to develop appropriate policies on how to return results to patients involved in research studies. These results may come in a variety of forms, ranging from aggregated study results to individual results to incidental findings. Experts disagree over the optimal timing, how researchers should consider the burden that these results can place on patients, and whether there are circumstances in which certain findings should be withheld. Is clinical utility the appropriate standard, or does mere curiosity suffice to trigger disclosure obligations? How certain must the results be, and what if there is reason to believe that the results will be difficult for participants to understand – or cause them harm?  Two experts in the field of research law and ethics will join us to engage these and other questions, and help conceive a way to move forward in the best interests of patients and the medical research enterprise.
EXPERTS:
Barbara Bierer, MD
Program Director, Regulatory Foundations, Law and Ethics Program, Harvard Catalyst
​Faculty co-director, Multi-Regional Clinical Trials (MRCT) Center of Brigham and Women's Hospital and Harvard Medical School

Pilar Ossorio, JD, PhD
​Professor of Law and Bioethics
​University of Wisconsin Law School
MODERATOR:
​
Holly Lynch, JD, MBioethics 
Executive Director, 
Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
​Harvard Law School

Clinical Trial Data Sharing and Reproducibility
​December 7, 2016 |  Harvard Medical School

​
In January, the International Committee of Medical Journal Editors proposed requiring investigators make de-identified trial data available six months after publication as a precondition of consideration. Many data scientists support the policy and champion even more stringent standards as a means to accelerate scientific advances, tackle the problem of irreproducibility, and fulfill moral obligations to research participants. However, numerous trialists have raised potential challenges in the push toward greater data sharing, including researchers analyzing data with which they are not intimately familiar, diminished incentives for primary data collection, and shared data usability.
 
The ongoing debate has exposed a number of important questions regarding the ownership of publicly and privately funded trial data, the ethical duties of society and researchers to trial participants, and the possible benefits and harm of rapid widespread data sharing.
EXPERTS:
Jeff Drazen, MD
Editor-In-Chief, New England Journal of Medicine
Distinguished Parker B. Francis Professor of Medicine, Harvard Medical School

Harlan Krumholz, MD, SM
Harold H. Hines, Jr. Professor of Medicine (Cardiology)
Director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital

​MODERATOR: 
​Ameet Sarpatwari, JD, PhD
Assistant Director, Program on Regulation, Therapeutics, and Law (PORTAL)
Instructor of Medicine, Harvard Medical School

The Hope and Hype of Precision Medicine
​November 16, 2016 |  Harvard Medical School

There has been considerable hype surrounding personalized and precision medicine in the past few years—including President Obama’s 2015 announcement of $215 million for the Precision Medicine Initiative. While some policymakers hail this movement as a pending revolution in healthcare, other commentators are skeptical, arguing that the same funding directed toward the social and behavioral determinants of health would yield far greater gains in terms of patient benefits and healthcare savings.
How important is precision medicine for our healthcare marketplace, and what should the expected outcomes be for public investment in research in this area?
EXPERTS:
Sandro Galea, MD, MPH, DrPH 
Dean and Robert A. Knox Professor
Boston University School of Public Health

Calum A. MacRae, MD, PhD
Chief of Cardiovascular Medicine and Associate Professor
Brigham & Women’s Hospital and Harvard Medical School
MODERATOR:
​
Spencer Hey, PhD
Faculty, Harvard Medical School Center for Bioethics
Research Fellow, PORTAL

Picture

International Trade and Access to Medicines
​October 14, 2016  |  Harvard Medical School

The Trans-Pacific Partnership (TPP) Agreement is intended to facilitate trade among 12 Asia-Pacific countries including the US, but its progress has been obstructed in part by ongoing controversy over provisions regarding intellectual property protections for pharmaceutical products. Some argue that if signed, the TPP will impact the availability or cost of essential medicines in low-income settings worldwide by requiring all countries to provide high levels of IP protections mirroring current US standards. Join us as we discuss the implications of the TPP for US patients (and patents), and the proper role of public health concerns in international trade negotiations.
Picture
EXPERTS:
Thomas Bollyky, JD
Senior Fellow for Global Health, Economics, and Development
Council on Foreign Relations


Amy Kapczynski, JD
Professor of Law
Yale Law School

MODERATOR:
Jing Luo, MD, MPH
Clinical Research Fellow, PORTAL
Brigham and Women's Hospital
Instructor in Medicine, Harvard Medical School


The Ethical Involvement of Patients in FDA Regulatory Evaluation of New Products
September 9, 2016  |  Harvard Medical School

There is a growing push to incorporate patient voices more directly at the FDA in decisionmaking about investigational drugs, but what are the optimal parameters of patients' contributions? 
  • How should individual patient voices be weighed against the accumulated data about a drug?
  • Can we better educate patients to equip them to engage in discussions about trial design, statistics, and evaluation?
  • How should we consider financial relationships between patient advocacy groups and the pharmaceutical industry sponsor of a drug?
To address these and other questions, we will consider two recent cases: flibanserin (the "female Viagra") for hypoactive sexual desire disorder in women and eteplirsen for Duchenne muscular dystrophy. In both cases, patients had a substantial voice in the data collection and FDA review processes, leading to controversial outcomes.
EXPERTS:
Walid Gellad, MD, MPH
University of Pittsburgh, VA Medical Center


Diana Zuckerman, PhD
National Center for Health Research

MODERATOR:
​
Aaron S. Kesselheim, MD, JD, MPH
Brigham and Women’s Hospital and Harvard Medical School


Picture
Picture
Program On Regulation, Therapeutics And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
1620 Tremont Street, Suite 3030
Boston, MA 02120
CONTACT